• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Topical for acne vulgaris

Article

Ortho Dermatologics has announced that RETIN-A MICRO® (tretinoin) gel microsphere 0.06% is now available commercially to healthcare professionals.

Ortho Dermatologics has announced that RETIN-A MICRO® (tretinoin) gel microsphere 0.06% is now available commercially to healthcare professionals. Studies have shown that the microsponge delivery system technology helps to control the release of tretinoin and improves photostability, even when used in conjunction with benzoyl peroxide, and a pump delivery system allows for controlled dispensing and consistent dosing.

The U.S. Food and Drug Administration (FDA) approved the Supplemental New Drug Application (sNDA) for RETIN-A MICRO® (tretinoin) gel microsphere 0.06% for topical application in the treatment of acne vulgaris on October 24, 2017.

FOR MORE INFORMATION: https://www.ortho-dermatologics.com

Recent Videos
Video 2 - 1 KOL featured in, "Adolescent Acne Management: Strategic Approaches and Leveraging Clascoterone Cream "
Video 1 - 1 KOL featured in, "Comprehensive Acne Management: Exploring the Role of Combination and Food Independent Treatments in an Adolescent Treatment-Naïve Patient "
Heather Woolery-Lloyd, MD, FAAD, an expert on acne
Heather Woolery-Lloyd, MD, FAAD, an expert on acne
Heather Woolery-Lloyd, MD, FAAD, an expert on acne
Heather Woolery-Lloyd, MD, FAAD, an expert on acne
© 2024 MJH Life Sciences

All rights reserved.